findmyKOL
Clinical trialNCT04237584TerminatedPhase 3Interventional

A Study Comparing ARB With Radium-223 vs ARB Therapy With Placebo and the Effect Upon Survival for mCRPC Patients

SponsorMANA RBMEnrollment23Metastatic Castration-resistant Prostate Cancer
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Research Site

    Myrtle Beach, South Carolina, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Darolutamide during Lead-in PeriodEnzalutamide during Lead-in PeriodLead-in Darolutamide followed by PlaceboLead-in Darolutamide followed by Radium-223Lead-in Enzalutamide followed by PlaceboLead-in Enzalutamide followed by Radium-223
Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
30 Jun 2020
Primary completion
7 Mar 2022
Completion
7 Mar 2022
Last update posted
7 Oct 2022
Registered enrollment
23
Registry id
NCT04237584
clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.